N

Median Age (Range)

Regimen

Histologies

R

(%)

HIV

(%)

ORR

(%)

CR (%)

2 Year EFS (%)

2 Year OS (%)

TRM

(%)

Completed Therapy (%)

Magrath [3]

(1996)

41

Child = 12; Adult = 25

(3 - 59)

Protocol 89-C-41 (CODOX-M IVAC)

SNCL

0

0

100

95

92

95^h

0

93

Mead [7] (2002)

52

35

(16 - 60)

Modified 89-C-41^a

BL only, defined by morphology and Ki-67 of 100%

0

0

87

77

65

73

12

79

Lacasce [6]

(2004)

14

47

(18 - 65)

Modified 89-C-41^b

BL and BCL-U, defined by morphology and Ki-67 > 90%

0

0

86

86

64^f

71

0

100

Mead [5]

(2008)

110

37

(17 - 76)

Modified 89-C-41^c

Aggressive B cell lymphoma with Ki67 fraction approaching 100%ⁱ

0

0

N/A

N/A

64^f

67

17

72

Maruyama [9]

(2010)

15

39

(19 - 59)

Modified 89-C-41^d

R day 1 each cycle

4BL and 11 intermediate DLBCL/BL

60

0

87

87

87

87

0

80

Barnes [18]

(2011)

80

46

(17 - 78)

Modified 89-C-41^b

R day 1 each cycle

BL, defined by REAL or WHO criteria at diagnosis

50

18

89

88

68^g

71^g

6

87

Mohamedbhai [10] (2011)

23

NR

(19 - 65)

89-C-41

R days 1, 10 each cycle

BCNHL with proliferation index > 95%

100

0

87

61

N/A

83^h

0

91

Corazzelli [11] (2012)

30

52

(25 - 77)

Modified

89-C-41

R days 1 of each cycle^e

BL and BCL-U, defined by morphology

100

0

93

93

78^j

82^j

0

80

Wasterlid [17] (2013)

32

42

Modified 89-C-41^a

R days 1 of each cycle^e

BL only, defined by morphology and Ki-67 of >95%

44

0

NR

NR

NR

69

NR

NR

Present study

31

45

(20 - 74)

Modified 89-C-41^a

BL and BCL-U, defined by morphology

71

0

68

65

62^f

69

16

71